



World Health
Organization

CONSOLIDATED HIV STRATEGIC
INFORMATION GUIDELINES

DRIVING IMPACT THROUGH PROGRAMME MONITORING AND MANAGEMENT

EXECUTIVE SUMMARY

APRIL 2020

The text of the Consolidated strategic information guidelines, April 2020, is available online at: <https://apps.who.int/iris/bitstream/handle/10665/331697/9789240000735-eng.pdf>



World Health
Organization

CONSOLIDATED HIV STRATEGIC
INFORMATION GUIDELINES

**DRIVING IMPACT
THROUGH PROGRAMME
MONITORING AND
MANAGEMENT**

EXECUTIVE SUMMARY

APRIL 2020

Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Executive summary

ISBN 978-92-4-000456-6 (electronic version)

ISBN 978-92-4-000457-3 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Executive summary. Geneva: World Health Organization; 2020. Licence: **CC BY-NC-SA 3.0 IGO**.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.



EXECUTIVE SUMMARY

In the health sector response to the HIV epidemic, collection, analysis and use of data are crucial at every level, from patient care and monitoring through programme management and national programme monitoring to global monitoring. This strategic information answers the questions: “How are patients doing?”, “How is the programme performing?” and “How can we do better?” Without these answers, the response to the HIV epidemic would be wandering in the dark.

Objectives. These guidelines – an update to the World Health Organization’s 2015 publication *Consolidated strategic information guidelines* – present a set of essential aggregate indicators and guidance on choosing, collecting and systematically analysing strategic information to manage and monitor the national health sector response to HIV.

Specifically, for programme management, these guidelines seek to strengthen programmes’ ability to identify and close gaps in service access, coverage and quality across the HIV services cascade, from primary prevention to knowing one’s HIV status to viral suppression.

For programme monitoring, these guidelines seek to optimize and align national reporting used to assess countries’ progress toward the 2030 95–95–95 HIV Fast Track goals – 95% of HIV-positive people knowing their status; 95% of people who know their HIV-positive status on treatment; and 95% of those on treatment virally suppressed – and towards Sustainable Development Goal 3.3, which calls for ending the HIV epidemic, as indicated by reduced incidence.

Audience. This guide is intended primarily to serve the needs of HIV programme staff in countries and their partners engaged in the collection, analysis and use of HIV-related strategic information at all levels of the health sector, including the health facility. These updated strategic information guidelines address issues relevant both to countries using aggregate electronic data systems and to countries entering data into individual-level information systems, such as electronic medical records.

Why collect and use strategic information?

- Strategic information provides the critical evidence that programme directors and line managers need to make informed decisions that improve programmes at all levels.
- Documenting outputs, outcomes and impact is crucial to the focus and sustainability of programmes.
- The availability of information is central to the accountability and transparency of decision-making by policy-makers.

The recommended indicators

The priority indicator set and guidance recommended here reflect the current state of the changing HIV epidemic, including programme innovations and investments deemed necessary for an effective response. These guidelines have been updated to reflect updates in WHO's HIV guidance since 2015, updates that encompass pre-exposure prophylaxis (PrEP), prevention for adolescent girls and young women, HIV testing, antiretroviral treatment (ART), viral load (VL), tuberculosis/HIV and elimination of mother-to-child transmission.

The recommended indicators fall into four sets:

- **National core indicators** – a set of 15 indicators essential for tracking progress against national targets. The national core indicators gauge critical aspects of coverage and quality and highlight international strategic, programmatic and clinical imperatives. These 15 indicators are widely applicable across different country contexts and are recommended for all countries.
- **National priority indicators (the Top 40)** – a set of 40 indicators (the 15 national core indicators plus an additional 25 indicators) that in real time provide programme managers the information and evidence needed to improve services and, at the same time, are feasible to collect. The Top 40 indicators are those most relevant to effective programme management in keeping with national strategy and clinical guidelines anchored in WHO technical guidelines.
- **Differentiated use** – In addition, these guidelines recommend a set of indicators of high utility for certain countries. Such countries are differentiated by specific epidemiologic characteristics – in particular, a high burden of co-morbidities of HIV and tuberculosis or hepatitis B and C; certain programme investments – in particular, voluntary medical male circumcision (VMMC) in countries with high HIV prevalence and low male circumcision prevalence; or special programme gaps – in particular, a need to increase injection safety or blood safety.
- **Impact and burden** – a set of modelled indicators, complementary to the programme-based Top 40, that quantify changes in the epidemic and monitor the effectiveness of the response. This set of indicators is considered an essential component of data reviews in all countries. It includes HIV incidence, which is the Sustainable Development Goal indicator for HIV.

Organization of the guidelines

These guidelines consist of three parts:

Part 1, Strategic information: a consolidated framework, provides the overall rationale for the use of strategic information for monitoring and managing the health sector response to the HIV epidemic and positions this guidance in the context of the global strategy for ending AIDS.

Part 2, Strong SI systems for effective decision-making, focuses on selecting and prioritizing country-specific indicator sets. This section lays out the rationale for the selection of the national core and national priority indicator sets and then offers considerations for adjusting the recommended sets to suit country contexts. Finally, this section outlines key components of a strong strategic information system built around the priority indicators.

Part 3, Recommended indicators: national core and priority, gives specific information about each of the recommended indicators. It organizes the Top 40 indicators into the following programme areas:

- reducing new infections (prevention)
- knowing status and linkage to treatment
- treatment and viral load (VL) suppression
- reducing mortality from TB/HIV
- preventing vertical transmission
- reducing co-morbidity with sexually transmitted infections
- zero discrimination
- special population groups – key populations, paediatric and adolescent, adolescent girls and young women
- differentiated use
- burden and impact.

Each of these sections includes a brief description of critical measurement issues influencing the selection of indicators for that programme area, a table presenting short indicator definitions and alignment with other global indicator guidelines, with references to published materials that provide additional details for operationalizing the collection and use of the indicator data. The programme area sections are followed by reference sheets detailing the calculation, data sources and measurement approaches for each indicator.

Choosing national indicators

WHO encourages national programmes to visualize their trajectory towards key response goals and to be forward-thinking and ambitious both in selecting indicators and in investing in the health information system needed to provide critical data. Doing so will equip programmes with the data that they need now and in the future to care for patients as well as to guide and tailor their programmes.

What's new in this guideline?

- An updated set of recommended indicators, with a differentiated approach for countries to prioritize and select indicators.
- The recommended indicators reflect updates in HIV technical guidelines and optimized alignment with changes in major global M&E frameworks since 2015.
- 40 priority national indicators (including 15 core indicators) to strengthen programme data use, with guidance on regular data reviews to identify gaps in the HIV services cascade.
- Improved digital content, with an accelerator kit, which helps to ensure that WHO's technical recommendations are accurately reflected in countries' digital data systems.

Criteria for selecting national indicators include:

- **Breadth:** Indicators reflect each step in the HIV services cascade, including prevention, and the extent and equity of services across geographic areas and population groups. Data are disaggregated by gender, age and location and, importantly, to assess services and impacts for key populations and other priority populations that are crucial to meeting national and global goals.
- **Depth:** Indicators speak to all three data use cases at country level: individual patient care and monitoring, programme management and programme monitoring (see figure).
- **Salience:** Indicators address priority programme areas, the largest investments of the national strategy and budget, and current critical service delivery issues.
- **Parsimony:** While coverage is complete, it is accomplished with the minimum number of indicators necessary. Fewer than 40 indicators may be enough. A focus on a few indicators with appropriate disaggregations can be powerful.
- **Feasibility:** Systems and personnel are capable of – and supported for – collecting, reporting, analysing and interpreting the data. An important determination of feasibility is the capacity of the health information system. For example, individual-level data in an electronic system are preferable for multiple reasons: better data quality, greater ease of disaggregation and more flexibility for subgroup analysis, and they can be used to monitor patient care across time and service locations. However, individual-level data systems require greater human resources and infrastructure for data entry and management.
- **Balance of sources:** The indicator set emphasizes routine programme data while balancing needs for survey-based data to fully address availability, representativeness and feasibility of data collection.

Health data use cases



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24668

